Hana Müllerova1, Diego J Maselli2, Nicholas Locantore3, Jørgen Vestbo4, John R Hurst5, Jadwiga A Wedzicha6, Per Bakke7, Alvar Agusti8, Antonio Anzueto9. 1. Respiratory Epidemiology, GlaxoSmithKline R&D, Uxbridge, England. 2. Audie L. Murphy Hospital, South Texas Veterans Health Care System, San Antonio, TX; Division of Pulmonary Diseases/Critical Care Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX. 3. Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, NC. 4. Gentofte, Hellerup, Denmark; Respiratory Research Group, Manchester Academic Health Science Centre, University of Manchester, Manchester, England. 5. Centre of Inflammation and Tissue Repair, University College London, London, England. 6. Centre for Respiratory Medicine, University College London, London, England. 7. Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway. 8. Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; FISIB, CIBER Enfermedades Respiratorias, Mallorca, Spain. 9. Audie L. Murphy Hospital, South Texas Veterans Health Care System, San Antonio, TX; Division of Pulmonary Diseases/Critical Care Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX. Electronic address: anzueto@uthscsa.edu.
Abstract
OBJECTIVE: Exacerbations of COPD requiring hospital admission have important clinical and societal implications. We sought to investigate the incidence, recurrence, risk factors, and mortality of patients with COPD exacerbations requiring hospital admission compared with those without hospital admission during 3-year follow-up. Patients with COPD (N = 2,138) were identified from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) observational cohort. METHODS: An analysis of time to first event of hospital admission was performed using Kaplan-Meier curves and Cox proportional hazard regression adjusting for possible confounders. RESULTS: Of the 2,138 patients, 670 (31%) reported a total of 1,452 COPD exacerbations requiring hospital admission during the study period; 313 patients (15%) reported multiple events. A prior history of exacerbation of COPD requiring hospital admission was the factor associated with the highest risk of a new hospitalization for exacerbation (hazard ratio, 2.71; 95% CI, 2.24-3.29; P < .001). Other risk factors included more severe airflow limitation, poorer health status, older age, radiologic evidence of emphysema, and higher WBC count. Having been hospitalized for exacerbation significantly increased the risk of mortality (P < .001). CONCLUSIONS: Exacerbations of COPD requiring hospital admission occur across all stages of airflow limitation and are a significant prognostic factor of reduced survival across all COPD stages. Patients with COPD at a high risk for hospitalization can be identified by their past history for similar events, and other factors, including the severity of airflow limitation, poor health status, age, presence of emphysema, and leukocytosis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00292552; URL: www.clinicaltrials.gov.
OBJECTIVE: Exacerbations of COPD requiring hospital admission have important clinical and societal implications. We sought to investigate the incidence, recurrence, risk factors, and mortality of patients with COPD exacerbations requiring hospital admission compared with those without hospital admission during 3-year follow-up. Patients with COPD (N = 2,138) were identified from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) observational cohort. METHODS: An analysis of time to first event of hospital admission was performed using Kaplan-Meier curves and Cox proportional hazard regression adjusting for possible confounders. RESULTS: Of the 2,138 patients, 670 (31%) reported a total of 1,452 COPD exacerbations requiring hospital admission during the study period; 313 patients (15%) reported multiple events. A prior history of exacerbation of COPD requiring hospital admission was the factor associated with the highest risk of a new hospitalization for exacerbation (hazard ratio, 2.71; 95% CI, 2.24-3.29; P < .001). Other risk factors included more severe airflow limitation, poorer health status, older age, radiologic evidence of emphysema, and higher WBC count. Having been hospitalized for exacerbation significantly increased the risk of mortality (P < .001). CONCLUSIONS: Exacerbations of COPD requiring hospital admission occur across all stages of airflow limitation and are a significant prognostic factor of reduced survival across all COPD stages. Patients with COPD at a high risk for hospitalization can be identified by their past history for similar events, and other factors, including the severity of airflow limitation, poor health status, age, presence of emphysema, and leukocytosis. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00292552; URL: www.clinicaltrials.gov.
Authors: Evelyn Tsantikos; Maverick Lau; Cassandra Mn Castelino; Mhairi J Maxwell; Samantha L Passey; Michelle J Hansen; Narelle E McGregor; Natalie A Sims; Daniel P Steinfort; Louis B Irving; Gary P Anderson; Margaret L Hibbs Journal: J Clin Invest Date: 2018-04-30 Impact factor: 14.808
Authors: Jennifer S Albrecht; Bilal Khokhar; Ting-Ying Huang; Yu-Jung Wei; Ilene Harris; Patience Moyo; Peter Hur; Susan W Lehmann; Giora Netzer; Linda Simoni-Wastila Journal: Respir Med Date: 2017-06-03 Impact factor: 3.415
Authors: Rosanne J H C G Beijers; Bram van den Borst; Anne B Newman; Sachin Yende; Stephen B Kritchevsky; Patricia A Cassano; Douglas C Bauer; Tamara B Harris; Annemie M W J Schols Journal: J Am Med Dir Assoc Date: 2016-02-23 Impact factor: 4.669
Authors: Hana Müllerova; Heather Gelhorn; Hilary Wilson; Victoria S Benson; Niklas Karlsson; Shailendra Menjoge; Stephen I Rennard; Maggie Tabberer; Ruth Tal-Singer; Debora Merrill; Paul W Jones Journal: Chronic Obstr Pulm Dis Date: 2017-03-28
Authors: Thomas Keller; Laura J Spece; Lucas M Donovan; Edmunds Udris; Scott S Coggeshall; Matthew Griffith; Alexander D Bryant; Richard Casaburi; J Allen Cooper; Gerard J Criner; Philip T Diaz; Anne L Fuhlbrigge; Steven E Gay; Richard E Kanner; Fernando J Martinez; Ralph J Panos; David Shade; Alice Sternberg; Thomas Stibolt; James K Stoller; James Tonascia; Robert Wise; Roger D Yusen; David H Au; Laura C Feemster Journal: Chest Date: 2020-04-09 Impact factor: 9.410
Authors: Amit D Parulekar; Carlos Martinez; Chu-Lin Tsai; Nicholas Locantore; Mustafa Atik; Abebaw M Yohannes; Christina C Kao; Hassan Al-Azzawi; Ali Mohsin; Robert A Wise; Marilyn G Foreman; Dawn L Demeo; Elizabeth A Regan; Barry J Make; Aladin M Boriek; Laura E Wiener; Nicola A Hanania Journal: J Am Med Dir Assoc Date: 2017-12-01 Impact factor: 4.669